APA (7th ed.) Citation

X, L., Y, Z., KY, Y., N, Z., F, J., GR, Z., . . . J, M. (2024). Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet (London, England), 403(10445), 2720. https://doi.org/10.1016/S0140-6736(24)00594-4

Chicago Style (17th ed.) Citation

X, Liu, et al. "Induction-concurrent Chemoradiotherapy with or Without Sintilimab in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma in China (CONTINUUM): A Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial." Lancet (London, England) 403, no. 10445 (2024): 2720. https://doi.org/10.1016/S0140-6736(24)00594-4.

MLA (9th ed.) Citation

X, Liu, et al. "Induction-concurrent Chemoradiotherapy with or Without Sintilimab in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma in China (CONTINUUM): A Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial." Lancet (London, England), vol. 403, no. 10445, 2024, p. 2720, https://doi.org/10.1016/S0140-6736(24)00594-4.